RecruitingPhase 2Phase 3NCT07287644

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa

Sponsor

Bluefin Biomedicine, Inc.

Enrollment

210 participants

Start Date

Nov 3, 2025

Study Type

INTERVENTIONAL

Conditions

Hidradenitis Suppurativa (HS)

Summary

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called BFB759 and Placebo for BFB759 for people with hidradenitis suppurativa (hs). The study is currently recruiting participants at 58 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBFB759

BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including hidradenitis suppurativa.

OTHERPlacebo for BFB759

Placebo for BFB759

Locations(58)

Saguaro Dermatology

Phoenix, Arizona, United States

Encino Research Center

Encino, California, United States

Clinical Science Institute

Santa Monica, California, United States

Skin Care Research

Boca Raton, Florida, United States

Center for Skin Science and Innovation

Fort Lauderdale, Florida, United States

Ziaderm Research LLC

North Miami Beach, Florida, United States

Clinical Trials Management, LLC

Tampa, Florida, United States

DelRicht Research

Atlanta, Georgia, United States

Southeast Research Specialist LLC

Douglasville, Georgia, United States

The Indiana Clinical Trials Center, PC

Plainfield, Indiana, United States

DS Research of Kentucky

Louisville, Kentucky, United States

Martha Stewart

Mandeville, Louisiana, United States

Clinical Trials Management, LLC

Metairie, Louisiana, United States

DelRicht Research

New Orleans, Louisiana, United States

Oakland Hills Dermatology

Auburn Hills, Michigan, United States

MI Skin Innovations

Northville, Michigan, United States

DelRicht Research

Wildwood, Missouri, United States

JDR Dermatology Research LLC

Las Vegas, Nevada, United States

Skin Cancer and Dermatology Institute

Reno, Nevada, United States

Schweiger Dermatology, PC

Hackensack, New Jersey, United States

Equity Medical LLC

The Bronx, New York, United States

Optima Research - Boardman

Boardman, Ohio, United States

Apex Clinical Research Center, LLC

Canton, Ohio, United States

Apex Clinical Research Center, LLC

Mayfield Heights, Ohio, United States

UPMC Department of Dermatology

Pittsburgh, Pennsylvania, United States

Medical Univ of SC Department of Dermatology

Charleston, South Carolina, United States

DelRicht Research

Mt. Pleasant, South Carolina, United States

DelRicht Research

Smyrna, Tennessee, United States

DelRicht Research

Prosper, Texas, United States

Stryde Research-Epiphany Dermatology

Southlake, Texas, United States

Dermatology Specialists of Spokane

Spokane, Washington, United States

Medical Center Medconsult Burgas EOOD

Burgas, Bulgaria

Medical Center Medconsult Pleven-Lovech Branch

Lovech, Bulgaria

Medical Center Medconsult Pleven OOD

Pleven, Bulgaria

Medical Center Etika Ambulatory For Specialized Outpatient Medical Care OOD

Plovdiv, Bulgaria

Medical Center Rusemed

Rousse, Bulgaria

York Dermatology Clinical and Research Centre

Richmond Hill, Ontario, Canada

North York Research Inc.

Toronto, Ontario, Canada

CCR Ostrava s.r.o.

Ostrava, Czechia

Pratia Pardubice a.s.

Pardubice, Czechia

Sanatorium of Professor Arenbergera

Prague, Czechia

St. Josef-Hospital Bochum

Bochum, Germany

Universitatsklinikum Frankfurt Klinik fur Dermatologie, Venerologie und Allergologie

Frankfurt, Germany

University Clinic Dermatology Heidelberg

Heidelberg, Germany

University Hospital, Leipzig

Leipzig, Germany

University of Luebeck

Lübeck, Germany

Klinik und Poliklinik fur Dermatologie und Allergologie

Munich, Germany

NZOZ Specjal. Osrodek Dermatologiczny DERMAL

Bialystok, Poland

Luxderm Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska

Lublin, Poland

Melita Medical

Wroclaw, Poland

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

Wroclaw, Poland

Wojewódzki Szpital Specjalistyczny we Wrocławi,Oddział Dermatologiczny

Wroclaw, Poland

Hospital Universitario Virgen De Las Nieves

Granada, Spain

Hospital Asil de Granollers

Granollers, Spain

Hospital Universitario de Gran Canaria Doctor Negrin

Las Palmas de Gran Canaria, Spain

Hospital Gregorio Maranon

Madrid, Spain

Complejo Hospitalario Universitario de Pontevedra

Pontevedra, Spain

Hospital de Manises

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07287644

Related Trials

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498318 locations

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

NCT074895737 locations

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa

NCT06932003

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT0721397330 locations